News

Filter

Current filters:

SpirivaAlmirall

EU Commission closes antitrust case in Boehringer/Almirall dispute over COPD drugs

07-07-2011

The European Commission has closed an antitrust investigation into allegations by Spain’s largest…

AlmirallBoehringer IngelheimEuropeLegalPatentsPharmaceuticalRespiratory and PulmonarySpiriva

Almirall/Forest set to file aclidinium for COPD by early 2012

07-05-2009

Leading Spanish drugmaker Almirall and its US partner Forest Laboratories have started implementing a…

AlmirallBoehringer IngelheimForest LaboratoriesSpirivatiotropium

Almirall's nine-month profit jumps 5.3%

24-11-2008

Leading Spanish drugmaker Almirall's net income in the first nine months of 2008 reached 132.6 million…

AlmirallForest LaboratoriesSpirivatiotropium

Almirall defies critics to progress COPD drug

27-10-2008

Almirall, Spain's largest drugmaker, and US partner Forest Laboratories have confirmed that they plan…

AlmirallBoehringer IngelheimForest LaboratoriesSpirivatiotropium

Almirall tumbles 42% as COPD drug disappoints

15-09-2008

Shares in Laboratorios Almirall fell to a record low after the firm presented disappointing late-stage…

AlmirallEscitalopram OxalateForest LaboratoriesLexaproNovartisSpirivatiotropium

FDA launches safety review of Boeh Ing's Spiriva as pooled analysis shows stroke risk

31-03-2008

The US Food and Drug Adminsitration has launched a safety review of Spiriva (tiotropium), after German…

AlmirallBoehringer IngelheimPfizerSpirivatiotropium

Almirall's COPD drug aclidinium bromide is a potential jewel in the company's crown

10-12-2007

A recent press event held by Spain's leading drugmaker Almirall saw the unveiling of the a ground-breaking…

AlmirallBoehringer IngelheimNovartisPfizerShireSpirivatiotropium

Back to top